1. Home
  2. Labeler Index
  3. Terumo Corporation
  4. NDC Product Code: 53877-005 Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative

NDC 53877-005 Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative

View Dosage, Usage, Ingredients, Routes, UNII

Table of Contents

  1. Product Information
  2. Product Packages
  3. What is NDC 53877-005?
  4. Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative Uses
  5. Active Ingredients UNII Codes
  6. Inactive Ingredients UNII Codes

Product Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Get all the details for National Drug Code (NDC) 53877-005 in one place. This page breaks down everything you need to know about the NDC, including proprietary name, active and inactive substances, package configurations, billing units, labeler information, and routes of administration. It also includes enhanced data such as HCPCS codes, FDA product labels with images, UNIIs, and RxNorm cross-references. Whether you're a healthcare professional verifying drug data or a consumer researching medication, this NDC page helps you make informed, accurate decisions.

NDC Product Code:
53877-005
Proprietary Name:
Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative
Product Type: [3]
Labeler Name: [5]
Terumo Corporation
Labeler Code:
53877
Product Label ID:
06da7814-b638-424e-bb37-66be346040d2
FDA Application Number: [6]
BN880217
Marketing Category: [8]
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date: [9]
12-15-2009
End Marketing Date: [10]
01-01-2025
Listing Expiration Date: [11]
01-01-2025
Exclude Flag: [12]
D
Code Navigator:

Code Structure Chart

Product Details

What is NDC 53877-005?

The NDC code 53877-005 is assigned by the FDA to the product Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative which is product labeled by Terumo Corporation. The product's dosage form is . The product is distributed in 2 packages with assigned NDC codes 53877-005-01 30 bag in 1 case / 1 kit in 1 bag * 35 ml in 1 bag * 56 ml in 1 bag, 53877-005-21 24 bag in 1 case / 1 kit in 1 bag * 63 ml in 1 bag * 100 ml in 1 bag. This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

What are the uses for Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative?

Revised 8/96TERUFLEX® BLOOD BAG SYSTEMCPD/OPTISOL® SOLUTIONRead these instructions before use.INSTRUCTIONS FOR BLOOD COLLECTION: Use aseptic technique1. Confirm that all numbered tubing of each blood bag unit contains segment numbers.2. Make a loose knot in the donor tubing approximately 10 cm from needle unless alternate methods are used to seal tubing.3. Clamp donor tubing.4. Suspend primary bag as far as possible below the donor's arm.5. Apply blood pressure cuff or tourniquiet to donor's arm. Disinfect site of phlebotomy. If blood pressure cuff is used, inflate cuff to 60 mmHg.6. Remove needle protector and perform phlebotomy. Remove clamp to permit blood flow into primary bag. CAUTION Do not touch needle after removing the needle protector.7. Appropriately secure donor tubing to donor's arm.8. MIX BLOOD WITH ANTICOAGULANT AT SEVERAL INTERVALS DURING COLLECTION.9. Collect labeled volume of blood (+/- 10%).10. Tighten knot firmly after collection. Clamp between knot and needle. Sever donor tubing between knot and clamp. Collect blood samples.11. Reapply clamp to donor tubing; release pressure on donor's arm and remove needle. Seal donor tubing. CAUTION Discard tubing/phlebotomy needle unit according to institutional procedures.12. Immediately after collection, invert bag several times to assure blood and anticoagulant are well mixed.13. Strip blood from donor tubing into bag, mix well, and allow tubing to refill. Seal on or near X marks on donor tubing to provide numbered aliquots of anticoagulated blood for testing.14. Centrifuge unit to separate red cells from plasma.15.The time of addition of OPTISOL Solution may vary depending on the processing option selected. Add solution under one of the following conditions.a) After removal of plasma from freshly collected blood.b) Within 8 hours of blood collection if components are prepared.c) Within 72 hours of collection if blood is refrigerated immediately following collection.16. Snap CLIKTIP (incline closure device) of primary collection bag and transfer plasma into satellite bag. Clamp transfer tubing of satellite bag.17. Snap CLIKTIP of OPTISOL Solution bag and drain contents into primary bag containing red blood cells. Seal tubing of primary bag in two places, and cut between seals and separate from satellite bag(s).NOTE: For TERUFLEX double bags, seal OPTISOL Solution bag tubing in two places, and cut between seals. Discard OPTISOL Solution container.18. Invert the red cell- OPTISOL mixture several times to insure that the final AS-5 red cell product is well suspended.19. Store AS-5 Red Blood Cells between 1-6oC.20. Infuse AS-5 Red Blood Cells within 42 days of collection.For further processing, use standard component processing techniques.To open the blister package, peel the cover film back 4/5 of its length.After opening, unused bags may be stored for 30 days by returning cover film to original position and sealing with tape to prevent possible loss of moisture.CAUTIONS• THE PACKET OF AGELESS CONTAINED IN THIS PACKAGE ABSORBS OXYGEN AND GENERATES HEAT ON REMOVAL AND SHOULD BE HANDLED WITH CARE.• DISPOSE WITH PACKET IN TRAY.• DO NOT DISPOSE WITH WASTES CONTAINING VOLATILE OR FLAMMABLE MATERIALS.• DISCARD AGELESS PACKET WITHOUT OPENING.TERUMO CORPORATION44-1, 2-chome, Hatagaya, Shibuya-Ku, Tokyo, Japan®: Registered TrademarkN-BB-OP-A (4)

Which are Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative UNII Codes?

The UNII codes for the active ingredients in this product are:

Which are Teruflex Blood Bag System Anticoagulant Citrate Phosphate Dextrose (cpd) And Optisol Red Cell Preservative Inactive Ingredients UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

* Please review the disclaimer below.

Product Footnotes

[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

[6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

[8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

[10] What is the End Marketing Date? - This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.

[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".